Full Breakdown
Patient Death Highlights Safety Concerns in CAR-T Autoimmune Trials
By Drooid · · How we work
Core Event
Bristol Myers Squibb disclosed that a participant in its Phase 1 trial of an investigational chimeric antigen receptor T-cell (CAR-T) therapy for multiple sclerosis died after developing septic pneumonia. The patient initially exhibited motor symptoms that did not improve with standard autoimmune treatments, received a potent immunosuppressant, and subsequently succumbed to the infection, according to a company press release.
Background & Context
CAR-T therapies, originally developed for certain cancers, are now being explored for autoimmune diseases such as multiple sclerosis. Recent safety signals have emerged across the field. In September, Bristol Myers Squibb announced a pause on its CAR-T autoimmune studies after observing “transient and reversible inflammatory events” during routine monitoring. At roughly the same time, Novartis reported three deaths in its own CAR-T autoimmune programs, attributing them to severe immune over-activation.
Data & Statistics
- One death reported by Bristol Myers Squibb in the multiple sclerosis trial.
- Three deaths reported by Novartis in separate CAR-T autoimmune studies.
- The Bristol trial is a Phase 1 study, indicating early-stage evaluation of safety and dosing.
Official Statements & Responses
Bristol Myers Squibb stated that the patient’s death occurred despite the administration of a potent immunosuppressant and that the event underscores the need for careful safety monitoring. The company’s earlier September communication indicated a temporary halt to its CAR-T autoimmune programs pending further review of inflammatory events. Novartis, in its disclosure, highlighted the occurrence of immune-system over-activity leading to fatal outcomes in its trials, prompting heightened scrutiny from regulators and analysts.
Why It Matters
These incidents raise broader concerns about the translational safety of CAR-T technology beyond oncology. The deaths have prompted analysts and reporters to question the risk-benefit profile of applying highly engineered immune cells to chronic autoimmune conditions. Ongoing pauses and heightened regulatory oversight may delay the development timeline for CAR-T therapies targeting diseases such as multiple sclerosis, potentially affecting patients awaiting novel treatment options.